Phase III study results show ulcerative colitis patients treated with etrasimod achieved statistically significant improvements in clinical remission compared to placebo.
List view / Grid view
Ulcerative colitis (UC)
Two new analyses displayed positive data supporting Stelara for the treatment of Crohn's disease and ulcerative colitis.
Janssen has released abstracts for four studies evaluating Stelara® (ustekinumab) in Crohn's disease (CD) and ulcerative colitis (UC).
In the trial, 74 percent of participants responded to upadacitinib and 33 percent of patients achieved clinical remission.
YuflymaTM (CT-P17) has been approved for the treatment of thirteen chronic inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and psoriatic arthritis, in Europe.
A Phase I clinical trial of remestemcel-L delivered by an endoscope to patients with Crohn’s disease and ulcerative colitis has commenced.
AbbVie and Allergan have announced the Federal Trade Commission has accepted AbbVie's pending acquisition of Allergan for $63 billion.
The European Commission has granted marketing authorisation to Stelara (ustekinumab) to treat patients aged six to 11 with moderate to severe plaque psoriasis.
This article highlights the 10 most popular news stories published by European Pharmaceutical Review in 2019.
Janssen has recently received marketing authorisation from the European Commission for Stelara to treat ulcerative colitis. Dr Jaime Oliver discusses the mode of action and why the treatment is needed.
The seven centres will aid disease research and clinical development, improving access to patient data for studies.
The biologic treatment ustekinumab has been granted an expanded use for ulcerative colitis within the EU.